87743-10-0

Basic information

• Product Name: 3-[(DIMETHYLAMINO)METHYL]-4-HYDROXY-5-METHOXYBENZENECARBALDEHYDE
• Synonyms: 3-[(DIMETHYLAMINO)METHYL]-4-HYDROXY-5-METHOXYBENZENECARBALDEHYDE;3-[(Dimethylamino)methyl]-4-hydroxy-5-methoxybenzenecarboxaldehyde;2-[(Dimethylamino)methyl]-4-formyl-6-methoxyphenol, N,N-Dimethyl-5-formyl-2-hydroxy-3-methoxybenzylamine;3-((diMethylaMino)Methyl)-4-hydroxy-5-Methoxybenzaldehyde;3-[(Dimethylamino)methyl]-4-hydroxy-5-methoxybenzaldehyde95%
• CAS NO: 87743-10-0
• Molecular Formula: C₁₁H₁₅NO₃
• Molecular Weight: 209.24
• Mol File: 87743-10-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 140-141
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-[(DIMETHYLAMINO)METHYL]-4-HYDROXY-5-METHOXYBENZENECARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(DIMETHYLAMINO)METHYL]-4-HYDROXY-5-METHOXYBENZENECARBALDEHYDE(87743-10-0)
• EPA Substance Registry System: 3-[(DIMETHYLAMINO)METHYL]-4-HYDROXY-5-METHOXYBENZENECARBALDEHYDE(87743-10-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 87743-10-0(Hazardous Substances Data)

Usage

General Description

The chemical compound 3-[(dimethylamino)methyl]-4-hydroxy-5-methoxybenzenecarbaldehyde is a derivative of benzaldehyde that possesses a dimethylamino group and a hydroxy and methoxy substitution on the benzene ring. It is commonly used in synthetic chemistry and pharmaceutical research as a building block for the synthesis of various organic compounds. This chemical may have potential applications in the development of pharmaceuticals, dyes, and fragrances due to its unique structural properties and functional groups. Its presence of a hydroxy group suggests potential antioxidant and antibacterial properties, while the presence of a dimethylamino group may also indicate potential medicinal or biological activity. Overall, the compound possesses diverse chemical properties that make it valuable for various industrial and research applications.

Upstream product

• 50-00-0 formaldehyd 
• 121-33-5 vanillin 
• 124-40-3 dimethyl amine 

Downstream Products

• 1198079-04-7 C₂₄H₂₈N₂O₆S₂ 
• 46274-23-1 2-(3,4-dimethoxy-5-methylphenyl)ethan-1-amine 
• 3153-96-6 1,2-dimethoxy-3-methyl-5-(2-nitro-vinyl)benzene 
• 80547-80-4 3,4-dimethoxy-5-methylbenzaldehyde 
• 82628-68-0 3,4-dihydroxy-5-methylbenzaldehyde 
• 32263-14-2 4-hydroxy-3-methoxy-5-methylbenzaldehyde 
• 28276-04-2 3-(chloromethyl)-4-hydroxy-5-methoxybenzaldehyde 
• 2134-91-0 4-hydroxy-5-methoxyisophthalic acid 
• 87743-11-1 Acetic acid 2-acetoxymethyl-4-formyl-6-methoxy-phenyl ester 
• 2931-90-0 5-formylvanillin 
• 1198079-02-5 C₁₄H₁₅NO₄S₂ 

Relevant articles and documents

Application of conjugate of polyethylene glycol and local anesthetic to non-narcotic analgesia

The invention discloses application of a conjugate of polyethylene glycol and local anesthetic to non-narcotic analgesia. The local anesthetic is made into a prodrug or a sustained release preparation, wherein high-molecular polymers such as polyethylene glycol in the prodrug are covalently bonded with local anesthetic, and auxiliary materials with a sustained release function in the sustained release preparation are covalently bonded with the local anesthetic. After application of the conjugate, anesthesia and analgesia effects are not achieved until release of free local anesthetic, and an analgesia effect is achieved after release of the free local anesthetic. Due to low release speed of the prodrug or the sustained release preparation of the local anesthetic, drug concentration can bestably and enduringly kept in an effective concentration range of non-narcotic analgesia, long-acting non-narcotic analgesia effects can be achieved while remarkable reduction of clinical untoward effects of the local anesthetic and reduction of dosing frequency are realized, drug effectiveness is improved, and a clinical application range of the local anesthetic is expanded.

Tetrahydrocoptisine derivative and applications thereof

The present invention relates to a compound as shown in a formula (VII), a preparation method and applications thereof in medicines. In particular, the present invention relates to a derivative of the compound as shown in the formula (VII), a preparation method, and the applications of the derivative used as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, II-type diabetes, hyperglycemia, obesity or insulin resistance syndrome and metabolic syndrome. The compound disclosed by the present invention can also reduce total cholesterol, LDL-cholesterol and triglyceride, and increases expression of a liver LDL receptor and decreases expression of PCSK9.

An expeditious and convergent synthesis of ailanthoidol

An expeditious and concise method has been described for the synthesis of ailanthoidol through convergent route starting from vanillin. The protocol involving intramolecular Wittig as a key reaction afforded ailanthoidol in overall high yield.